Thalidomide Zentiva (Thalidomide 50 mg)

What Is Thalidomide Zentiva and What Is It Used For?

Thalidomide Zentiva contains the active substance thalidomide, an immunomodulatory drug (IMiD) authorised for use in combination with melphalan and prednisone to treat adults with previously untreated multiple myeloma. It is primarily used in patients aged 65 years and older, or in younger patients who cannot receive high-dose chemotherapy with autologous stem cell transplantation.

Thalidomide Zentiva is a generic version of thalidomide, a medicine with one of the most complex histories in modern pharmacology. Originally marketed in the late 1950s as a sedative and anti-emetic for morning sickness, thalidomide was withdrawn in the early 1960s after it was recognised as the cause of a global epidemic of severe birth defects in children exposed in utero. More than four decades later, careful research revealed that the same drug possesses potent anti-cancer, anti-inflammatory and immunomodulatory properties. Thalidomide was reintroduced into clinical practice in 1998 under stringent regulatory controls, initially for a skin manifestation of leprosy (erythema nodosum leprosum) and subsequently for multiple myeloma.

Multiple myeloma is a cancer of plasma cells, a type of antibody-producing white blood cell that lives predominantly in the bone marrow. In myeloma, a single clone of abnormal plasma cells multiplies out of control, crowding out normal blood-forming cells and secreting excessive monoclonal immunoglobulin (paraprotein). The disease typically causes bone pain and fractures, anaemia, kidney impairment, recurrent infections and high blood calcium. Although multiple myeloma is generally incurable, contemporary therapy with combinations such as thalidomide-melphalan-prednisone (MPT), bortezomib, lenalidomide, daratumumab and autologous stem cell transplantation has substantially improved median survival, with many patients now living a decade or more after diagnosis.

Within the myeloma treatment landscape, Thalidomide Zentiva occupies a well-established place as a first-line oral therapy for older patients. The landmark French IFM 99-06 trial, published in The Lancet in 2007, was the first to demonstrate that adding thalidomide to melphalan and prednisone significantly improved both response rates and overall survival compared with melphalan and prednisone alone in patients aged 65 to 75. A subsequent Italian GIMEMA trial and multiple meta-analyses confirmed the survival benefit, and the MPT regimen remains a standard option recognised in major international guidelines including those of the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN).

Because Thalidomide Zentiva is a generic formulation, it is bioequivalent to the reference product (originally Thalidomide Celgene, later Thalidomide BMS). Generic thalidomide formulations have helped improve access to the medicine and reduce treatment costs in many health systems, while the clinical indications, dosing and strict safety programme remain identical across brands.

How Thalidomide Zentiva Works

Thalidomide exerts its anti-myeloma effect through several complementary mechanisms, which together make it more than a simple chemotherapy agent:

• Anti-angiogenesis: Thalidomide inhibits the formation of new blood vessels (neovascularisation) within the bone marrow, depriving myeloma cells of the vascular support they need to grow
• Direct anti-tumour activity: It induces apoptosis (programmed cell death) in malignant plasma cells, partly through binding to the cereblon protein within the CRL4-CRBN E3 ubiquitin ligase complex
• Immune stimulation: Thalidomide enhances the activity of T cells and natural killer (NK) cells against myeloma cells, and stimulates the release of interleukin-2 (IL-2) and interferon-gamma
• Cytokine modulation: By lowering tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), thalidomide disrupts the supportive bone marrow microenvironment that myeloma cells depend on
• Anti-inflammatory effects: Reduced inflammation contributes to improvements in bone disease and symptom control

The same properties explain why thalidomide is sometimes used off-label in carefully selected patients for conditions such as refractory erythema nodosum leprosum, Behçet's disease, graft-versus-host disease and certain HIV-associated wasting syndromes, although these indications are not authorised for Thalidomide Zentiva in most jurisdictions.

What Should You Know Before Taking Thalidomide Zentiva?

Before starting Thalidomide Zentiva, you must understand the mandatory Pregnancy Prevention Programme, the risk of blood clots (venous thromboembolism), the risk of permanent nerve damage (peripheral neuropathy), and the sedating effect of the medicine. Thalidomide must never be taken during pregnancy and must never be shared with anyone else.

Thalidomide Zentiva is subject to exceptional safeguards because of thalidomide's history as one of the most devastating iatrogenic tragedies in medical history. Before your first prescription, your doctor will explain the risks in detail, provide educational materials, confirm that you understand and agree to follow the Pregnancy Prevention Programme, and sign a patient agreement form.

Contraindications

You must not take Thalidomide Zentiva if any of the following apply to you:

• Pregnancy: If you are pregnant, suspect you may be pregnant or are actively trying to become pregnant. Thalidomide causes severe birth defects and fetal death
• Women of childbearing potential without compliance: If you are a woman of childbearing potential and cannot or will not meet all the requirements of the Pregnancy Prevention Programme, including use of effective contraception and regular pregnancy testing
• Breastfeeding: It is not known whether thalidomide is excreted in human milk, and breastfeeding during treatment is contraindicated
• Hypersensitivity: If you are allergic to thalidomide or any of the other ingredients listed in the capsule (including gelatin, titanium dioxide or the printing ink components)

Pregnancy Prevention Programme (PPP)

Because thalidomide is so profoundly teratogenic, every manufacturer, including Zentiva, operates a Pregnancy Prevention Programme that meets the requirements of the European Medicines Agency (EMA), the US Food and Drug Administration (FDA's REMS programme) and national regulators. Participation in the PPP is not optional: without a valid PPP record, the pharmacy cannot legally dispense Thalidomide Zentiva.

For women of childbearing potential

A woman is considered to be of childbearing potential unless she has had a hysterectomy or bilateral oophorectomy, has medically confirmed ovarian failure, or has had at least 24 consecutive months of natural menopause. The PPP requires:

• Use of at least one highly effective method of contraception (for example, a hormonal implant, intrauterine device, intrauterine system, tubal sterilisation or vasectomised partner) for at least 4 weeks before starting treatment, throughout the whole treatment period, and for 4 weeks after the last dose
• If a highly effective method cannot be used, two complementary methods must be used, for example a progestogen-only pill together with a condom
• A medically supervised pregnancy test with a sensitivity of at least 25 mIU/mL before the first prescription, after 4 weeks of contraception and before treatment starts
• Pregnancy tests every 4 weeks during treatment and 4 weeks after the last dose
• Immediate reporting of any missed period, unexpected bleeding, suspicion of pregnancy, or failure of contraception

For male patients

Thalidomide passes into semen at concentrations high enough to pose a theoretical risk to a female partner's fetus. Therefore, all male patients, regardless of vasectomy status, must:

• Use a condom during every sexual contact with a pregnant woman or a woman of childbearing potential who is not using highly effective contraception, throughout treatment and for at least 7 days after stopping
• Not donate sperm during treatment or for at least 7 days afterwards
• Inform the treating physician immediately if a female partner becomes pregnant

Warnings and Precautions

In addition to the Pregnancy Prevention Programme, you should tell your doctor before starting Thalidomide Zentiva if any of the following apply:

• Cardiovascular risk factors: Previous heart attack or stroke, smoking, high blood pressure, high cholesterol, diabetes, or a personal or family history of blood clots. Thalidomide substantially increases the risk of venous and arterial thromboembolism
• Pre-existing neuropathy: Any history of nerve damage, tingling or numbness in the hands or feet, or conditions that predispose to neuropathy such as diabetes or heavy alcohol use
• Cardiac conditions: Bradycardia (slow heart rate), heart block, heart failure or the need for a pacemaker
• Pulmonary hypertension: A rare but serious complication in which the blood pressure in the arteries of the lungs becomes elevated
• Low blood counts: Pre-existing anaemia, neutropenia or thrombocytopenia, or a history of febrile neutropenia
• Liver or kidney disease: Including abnormal baseline liver function tests
• Severe cutaneous adverse reactions (SCARs): Any previous episode of Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN) or drug reaction with eosinophilia and systemic symptoms (DRESS)
• Chronic viral infections: Hepatitis B, hepatitis C, HIV, or a history of varicella zoster (shingles). Thalidomide can reactivate latent viral infections
• High tumour burden: Patients with rapidly progressive myeloma are at risk of tumour lysis syndrome when starting treatment

Blood donation: You must not donate blood during treatment with Thalidomide Zentiva or for at least 7 days after the final dose. This rule protects recipients, who could be pregnant, from inadvertent thalidomide exposure through transfusion.

Children and adolescents: Thalidomide Zentiva is not recommended for use in people under 18 years of age. Safety and efficacy data in this age group are insufficient, and the Pregnancy Prevention Programme has not been validated for adolescents.

Pregnancy and Breastfeeding

Thalidomide is the paradigmatic example of a human teratogen. The so-called thalidomide disaster of the late 1950s and early 1960s, in which an estimated 10,000 to 20,000 children worldwide were born with limb and organ defects after in utero exposure, led directly to the creation of modern pre-marketing drug safety regulation, including the 1962 Kefauver-Harris Amendment in the United States and comparable reforms in Europe. The lesson learned from that tragedy is that pregnancy exposure to thalidomide must be prevented absolutely and by every available means.

If a woman becomes pregnant while taking Thalidomide Zentiva, treatment must be stopped immediately, and she should be referred to a physician who is experienced in teratology for evaluation and counselling. The case must also be reported to the marketing authorisation holder and the relevant regulatory authority so that the pregnancy outcome can be followed up.

Breastfeeding: It is not known whether thalidomide is excreted in human milk, but because of the risk of serious harm to a breastfed infant, breastfeeding during treatment is contraindicated. Women should discuss alternative feeding options with their doctor before starting therapy.

Driving and operating machinery: Thalidomide Zentiva commonly causes dizziness, somnolence, orthostatic hypotension, fatigue and occasionally blurred vision. These effects can impair your ability to drive, cycle, operate machinery or use power tools. Do not drive or perform these activities if you are affected, and plan your dosing (for example, at bedtime) to minimise daytime sedation.

How Does Thalidomide Zentiva Interact with Other Drugs?

Thalidomide Zentiva interacts with sedatives, opioids, anticoagulants, beta-blockers, hormonal contraceptives and other neurotoxic drugs. Alcohol amplifies its sedative effects and should be avoided. Always give your doctor and pharmacist a complete list of every medicine, supplement and herbal product you take before starting treatment.

Interactions with Thalidomide Zentiva fall into several clinically important categories: enhancement of central nervous system (CNS) depression, additive peripheral neuropathy, additive bradycardia, altered coagulation, and reduced contraceptive efficacy. The most serious consequences of an unrecognised interaction are severe sedation, falls, cardiac events, bleeding or thrombosis, and – most critically – an unplanned pregnancy in a woman of childbearing potential whose hormonal contraceptive has failed.

Major Interactions

The most dangerous interactions involve other sedating medicines. Thalidomide Zentiva is itself a strong sedative, and combining it with benzodiazepines, opioids, barbiturates, gabapentinoids, sedating antipsychotics or alcohol can cause profound central nervous system depression with respiratory compromise, especially in elderly patients. Falls and fall-related fractures are a particular concern in the population most commonly treated for multiple myeloma.

Hormonal contraceptives pose a dual problem. Some hormones may be metabolised differently during thalidomide therapy, potentially reducing efficacy, and combined oral contraceptives carry their own increased risk of venous thromboembolism, which adds to the baseline thrombosis risk from thalidomide. Women of childbearing potential should discuss contraception in detail with both their oncologist and a gynaecologist; intrauterine devices (IUDs), copper IUDs, subdermal implants and progestogen-only methods combined with a barrier method are usually preferred.

Combination with dexamethasone, commonly used alongside thalidomide in some second-line regimens, greatly increases the risk of deep vein thrombosis and pulmonary embolism. Guidelines recommend routine thromboprophylaxis with low-dose aspirin or, in patients with additional risk factors, low-molecular-weight heparin (LMWH) or a direct oral anticoagulant (DOAC).

Moderate Interactions

Beta-blockers, anticholinesterases (for example donepezil or pyridostigmine) and calcium-channel blockers such as diltiazem or verapamil can cause additive bradycardia. Heart rate and rhythm should be monitored, particularly in older patients and those with pre-existing conduction disease. Warfarin and direct oral anticoagulants do not have a strong pharmacokinetic interaction with thalidomide, but coagulation parameters should be monitored more frequently when therapy is initiated or stopped.

Digoxin requires careful monitoring because both medicines can slow the heart rate and because acute kidney injury during thalidomide treatment can raise digoxin levels. Regular ECG, electrolyte and digoxin level checks are prudent.

Vaccines and Thalidomide Zentiva

Patients with multiple myeloma are immunocompromised both by their disease and by combination chemotherapy. Live attenuated vaccines such as yellow fever, varicella, MMR, oral typhoid, oral polio and BCG are generally contraindicated during and for a period after thalidomide therapy. Inactivated vaccines, such as the seasonal influenza vaccine, inactivated polio, tetanus boosters, pneumococcal vaccines and most COVID-19 vaccines, are generally safe but may produce a reduced antibody response. Your haematology team will coordinate timing with any planned travel or routine immunisations.

What Is the Correct Dosage of Thalidomide Zentiva?

The standard adult dose of Thalidomide Zentiva is 200 mg (four 50 mg capsules) once daily at bedtime for patients under 75 years, and 100 mg (two 50 mg capsules) once daily at bedtime for patients aged 75 and over. Treatment is given in 6-week cycles in combination with melphalan and prednisone, for a maximum of 12 cycles.

Always take Thalidomide Zentiva exactly as your prescribing physician has instructed. Dose selection, schedule and duration are individualised according to your age, renal function, blood counts, tolerance of the medicine and response to therapy. The information below reflects the summary of product characteristics for the multiple myeloma indication and applies to most adults; your own prescription may differ.

Treatment Cycles

Thalidomide Zentiva is given as part of a 6-week (42-day) treatment cycle together with melphalan and prednisone. Within each cycle, melphalan (usually 0.25 mg/kg) and prednisone (usually 2 mg/kg) are taken orally for the first 4 consecutive days, while Thalidomide Zentiva is taken continuously every day of the 6-week cycle. The recommended maximum duration of treatment is 12 cycles (72 weeks or approximately 18 months). Your haematologist will assess your response before each cycle using blood tests (serum and urine protein electrophoresis, free light chains), imaging where indicated and clinical evaluation.

How to Take the Capsules

• Swallow the hard capsule whole with a full glass of water. Do not crush, open or chew it
• Take as a single bedtime dose to shift peak sedative effects into the sleep period
• Capsules may be taken with or without food; taking them with a light snack can reduce any gastrointestinal discomfort
• Remove capsules from the blister pack by pressing on one end only; pressing in the middle may damage the capsule and expose the powder
• If powder from a broken capsule comes into contact with your skin, wash the area thoroughly with soap and water. If it contacts mucous membranes, flush with plenty of water
• Healthcare professionals and caregivers should wear disposable gloves when handling blisters or capsules, particularly if they are pregnant or of childbearing potential

Dose Modifications

Your haematologist may reduce or interrupt your dose for several reasons. Common triggers include:

• Peripheral neuropathy: Any grade 2 or higher neuropathy typically leads to a dose reduction of 50 mg; grade 3 usually requires interruption of treatment until symptoms improve
• Severe neutropenia or thrombocytopenia: Treatment may be held until counts recover, with dose reduction for subsequent cycles
• Venous thromboembolism: Treatment is usually paused during anticoagulation initiation, then resumed with ongoing prophylaxis
• Skin reactions: Rash or photosensitivity may require dose reduction or permanent discontinuation, depending on severity
• Bradycardia, syncope or severe hypotension: Often leads to dose reduction or discontinuation

Missed Dose

If you forget to take Thalidomide Zentiva at your usual time:

• Less than 12 hours late: Take the missed dose as soon as you remember
• More than 12 hours late: Skip the missed dose entirely. Wait and take your next dose at the usual time the following evening

Never take a double dose to make up for a forgotten dose. If you are unsure, contact your pharmacist or nurse for advice.

Overdose

If you take more Thalidomide Zentiva than prescribed, go to the nearest emergency department immediately or telephone your local poison control centre. Bring the medicine packaging with you if possible. Symptoms of acute overdose may include severe drowsiness, confusion, bradycardia, hypotension, syncope and loss of consciousness. There is no specific antidote for thalidomide; treatment is supportive and may include cardiac monitoring and intravenous fluids. Haemodialysis is not expected to remove significant amounts of thalidomide.

What Are the Side Effects of Thalidomide Zentiva?

The most common side effects of Thalidomide Zentiva are peripheral neuropathy, constipation, drowsiness, dizziness, tremor, swelling of the limbs and reduced blood cell counts. Serious but less frequent events include venous thromboembolism, severe skin reactions, heart rhythm problems and, rarely, secondary cancers. Report any new or worsening symptoms to your doctor promptly.

Like all medicines, Thalidomide Zentiva can cause adverse effects, although not every patient experiences them. The side-effect profile is well characterised from decades of clinical use and from large randomised trials. Some effects are mild and reversible; others are serious and require prompt medical attention. The frequency categories below follow the standard European convention used in every approved summary of product characteristics.

Peripheral Neuropathy in Depth

Peripheral neuropathy is the most clinically important dose-limiting toxicity of thalidomide. It typically develops after several months of continuous treatment but can occur earlier, particularly in patients with diabetes or pre-existing nerve damage. Symptoms usually begin symmetrically in the feet and later involve the hands. They may include tingling, numbness, burning pain, impaired fine motor skills or gait unsteadiness. In some patients the neuropathy has an important motor component, with muscle weakness.

Early recognition and dose modification are essential. Your medical team will examine your reflexes, sensation and strength at regular intervals and may perform nerve conduction studies if symptoms develop. Reducing the dose or interrupting treatment at the first sign of neuropathy often allows partial or complete recovery over weeks to months. If treatment continues unchanged, the nerve damage can become severe and, in some patients, permanent. Supportive measures include vitamin B complex supplementation, physiotherapy, and medicines such as duloxetine, gabapentin or pregabalin for neuropathic pain.

Blood Clots and Cardiovascular Events

Thalidomide, and especially thalidomide combined with high-dose dexamethasone or other myelosuppressive chemotherapy, substantially increases the risk of venous thromboembolism (VTE). Reported rates of deep vein thrombosis and pulmonary embolism in the early randomised trials ranged from 3% to 15% depending on the combination and the use of prophylaxis. Arterial events – myocardial infarction and ischaemic stroke – have also been reported, though less commonly. Warning signs include:

• Deep vein thrombosis: Unilateral leg pain, swelling, redness, warmth or cramp, especially in the calf
• Pulmonary embolism: Sudden shortness of breath, pleuritic chest pain, cough (possibly with blood), rapid heart rate, fainting or sudden collapse
• Myocardial infarction: Chest pressure or pain radiating to the arm, jaw or back, with sweating, nausea and breathlessness
• Stroke: Sudden weakness or numbness of the face or limbs on one side, confusion, slurred speech or loss of vision

If any of these symptoms occur, seek emergency medical attention immediately. Almost all patients starting thalidomide combination therapy are offered thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin or a direct oral anticoagulant, based on an individual risk assessment.

How Should You Store Thalidomide Zentiva?

Store Thalidomide Zentiva in its original blister pack, out of the sight and reach of children at all times. No special temperature storage conditions are required. Do not use after the expiry date on the packaging, and return any unused capsules to your pharmacy after treatment ends.

Because of its teratogenic potential, the storage of Thalidomide Zentiva is governed by stricter rules than for most other oral medicines. The overriding principle is that no unauthorised person, and especially no child or pregnant woman, should ever come into contact with the capsules.

• Keep the medicine in its original carton and blister to protect it from light and moisture
• Store at room temperature (below 30°C); no refrigeration is required
• Always keep the medicine out of the sight and reach of children
• Do not use Thalidomide Zentiva after the expiry date (EXP) printed on the carton and blister; the expiry date refers to the last day of that month
• Do not use the medicine if the packaging appears damaged, tampered with or altered
• Never share your capsules with anyone else. Thalidomide Zentiva is prescribed for you personally and could cause severe harm to another person, particularly if she is pregnant or could become pregnant
• At the end of your treatment, return any unused or expired capsules to your pharmacy or dispensing centre. Do not flush the capsules down the toilet and do not dispose of them in household waste. Pharmacies participate in a drug take-back scheme that ensures safe destruction of controlled teratogens

What Does Thalidomide Zentiva Contain?

Each Thalidomide Zentiva hard capsule contains 50 mg of thalidomide as the active substance, together with inactive ingredients in the capsule filling, shell and printing ink.

Active Ingredient

Each hard capsule contains 50 mg of thalidomide. Thalidomide is a chiral molecule (IUPAC name 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione). It is supplied as the racemic mixture of the R- and S-enantiomers, which rapidly interconvert in vivo through a process called chiral inversion.

Other Ingredients (Excipients)

The typical composition of a generic thalidomide 50 mg hard capsule is:

• Capsule contents: Pregelatinised starch, magnesium stearate
• Capsule shell: Gelatin, titanium dioxide (E171)
• Printing ink: Shellac, black iron oxide (E172), propylene glycol, ammonium hydroxide

Thalidomide Zentiva does not contain lactose, gluten, sucrose, sodium benzoate or azo dyes. Patients with known hypersensitivity to any listed excipient should discuss alternatives with their physician or pharmacist.

Appearance and Pack Size

Thalidomide Zentiva is supplied as a white, opaque, hard gelatin capsule with black printing identifying the product and strength. The capsules are packaged in PVC/PVDC or aluminium blister strips and typically supplied in cartons of 28 capsules (2 blisters of 14). Pack sizes may vary between countries in line with local dispensing practice.

The marketing authorisation holder is Zentiva, k.s., Prague, Czech Republic, a pan-European generics manufacturer that also produces a wide range of other oncology and cardiovascular generics. Manufacturing and quality control are performed in facilities that comply with EU Good Manufacturing Practice (GMP) requirements.